Genistein Sensitizes Ovarian Cancer Cells to Chemotherapy
Author Information
Author(s): Solomon Leigh A, Ali Shadan, Banerjee Sanjeev, Munkarah Adnan R, Morris Robert T, Sarkar Fazlul H
Primary Institution: Karmanos Cancer Center, Wayne State University
Hypothesis
Can genistein enhance the effectiveness of cisplatin and other chemotherapeutic agents in treating platinum-resistant ovarian cancer cells?
Conclusion
Genistein can sensitize drug-resistant ovarian cancer cells to chemotherapy, potentially improving treatment outcomes.
Supporting Evidence
- Genistein pretreatment significantly reduced cell viability in both platinum-sensitive and resistant ovarian cancer cell lines.
- Combination treatment with genistein and chemotherapy agents led to increased apoptosis in ovarian cancer cells.
- Down-regulation of anti-apoptotic genes was observed in cells treated with genistein and chemotherapy.
Takeaway
This study found that a natural compound called genistein can help make ovarian cancer cells more responsive to chemotherapy, even when they are usually resistant.
Methodology
The study used human ovarian cancer cell lines to assess the effects of genistein pretreatment followed by combination treatments with cisplatin, taxotere, and gemcitabine.
Limitations
The study was conducted in vitro, and results may not fully translate to clinical settings.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website